报告：乳腺癌连续第五年成为研究最多的疾病
Breast cancer tops list of most-studied diseases for 5th year in a row: report
生命科学资讯
生物技术与制药领域的最新动态
安捷伦科技公司$A股被Cwm LLC收购 - MarketBeat
Agilent Technologies, Inc. $A Shares Purchased by Cwm LLC - MarketBeat
赛默飞世尔2025年第四季度财报：预测、发布日期及分析师展望 - 新闻与统计数据 - IndexBox
Thermo Fisher Q4 2025 Earnings: Forecast, Date, and Analyst Outlook - News and Statistics - IndexBox
Thermo Fisher Scientific下一季度财报预期展望 - MSN
What to expect from Thermo Fisher Scientific's next quarterly earnings report - MSN
波士顿信托华尔登公司增持赛默飞世尔科技股份 $TMO - MarketBeat
Boston Trust Walden Corp Grows Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
波士顿信托沃尔登公司减持171,941股沃特世公司股份
Boston Trust Walden Corp Sells 171,941 Shares of Waters Corporation $WAT - MarketBeat
Thermo Fisher Scientific下一季度财报预期展望 - 雅虎财经
What to Expect From Thermo Fisher Scientific's Next Quarterly Earnings Report - Yahoo Finance
Thermo Fisher Scientific下一季度财报预期——Barchart.com
What to Expect From Thermo Fisher Scientific's Next Quarterly Earnings Report - Barchart.com
细胞疗法CDMO市场即将迎来繁荣 |• 龙沙集团 • 药明康德 - openPR.com
Cell Therapy CDMO Market Is Going to Boom |• Lonza • WuXi AppTec - openPR.com
龙沙集团股票：是平静盘整还是为2026年蓄势待发？ - 特别报道
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
龙沙集团股票：2026年是平静盘整还是蓄势待发？ - 特别新闻
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
病毒组装中模糊核糖核蛋白复合物的演化
Evolution of a fuzzy ribonucleoprotein complex in viral assembly
皮肤表皮常驻记忆T细胞的适应性需要皮肤中的抗原接触
Epidermal resident memory T cell fitness requires antigen encounter in the skin
联邦法官在1月1日生效日前阻止340B药品定价试点计划。
Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective date
10x Genomics将在第44届摩根大通医疗健康年会上发表演讲 - Barchart.com
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Barchart.com
10x Genomics将在第44届摩根大通医疗健康年会上发表演讲 - PR Newswire
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
2025年12月22日至24日医疗科技股涨跌榜
Med-tech gainers and losers for Dec. 22-24, 2025
ASK制药达成中国权益协议；Unicycive在收到CRL后重新提交肾脏药物申请。
ASK Pharm makes China rights deal; Unicycive resubmits kidney drug after CRL
Nido Bio因二期临床试验数据不佳将停止运营。
Nido Bio to wind down after underwhelming Phase 2 data
随着基因编辑工具激增，终极技术探索仍在继续。
As gene editing tools multiply, the hunt for the final technology continues